Transparency concerns at drug pricing patient sessions

CMS is holding public listening sessions on Medicare price negotiations for the first 10 drugs selected, but reporting uncovered concerns patient advocates and the pharma industry have over transparency and potential conflicts of interest from some speakers. Host Ben Leonard talks with POLITICO health care reporter David Lim about the ties some speakers have to the industry or advocacy groups.